Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

NCT05179057 is registered in ClinicalTrials.gov with AlloVir as lead sponsor.

NCT NCT05179057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05179057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
AlloVir
Phase
Phase 3
Overall status
Terminated
Start date
April 26, 2022
Completion date
January 31, 2024
Enrollment
57 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

adenovirus infection